(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H335：Kann die Atemwege reizen.

• Sicherheit

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P304+P340：BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen.

(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  CHF-1301 was launched as an injection in Italy for the treatment of patients with Parkinson's disease, particularly those with complications in their clinical responses. CHF-1301 is the methyl ester of L-Dopa (levodopa), the immediate precursor of dopamine. Thus, this prodrug is more soluble in water at physiological pH, better absorbed and slowly transformed into levodopa in vivo; it consequently improves the duration of action and prevents the rapid fluctuations in response or involontary movements (dyskinesia) observed during chronic treatment with levodopa. In patients with a delayed effect of levodopa (on-phenomenon) or a severe resistance to L-Dopa (off-phenomenon), CHF- 1301 significantly improves the onset and the stability of the'response.

• Originator

  Chiesi Farmaceutici SpA (Italy)

• Definition

  ChEBI: Melevodopa is a tyrosine derivative.

• Trademarks

  Levomet

(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER Upstream-Materialien And Downstream Produkte

(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(18)Suppliers

7101-51-1, (S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER Verwandte Suche: